Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice

Hepatology Research

Volumn 38, Issue 11, 2008, Pages 1130-1139

  Geerts, Anja M ^a   Vanheule, Eline ^a   Van Vlierberghe, Hans ^a   Leybaert, Luc ^a   Van Steenkiste, Christophe ^a   De Vos, Martine ^a   Colle, Isabelle ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Angiogenesis; Hyperdynamic circulation; Portal hypertension; Sirolimus

Indexed keywords

CD31 ANTIGEN; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; MESENTERY BLOOD FLOW; MOUSE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPLANCHNIC BLOOD FLOW; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN LIGATION;

EID: 53349156840     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00369.x     Document Type: Article

References (34)

1. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: A role for nitric oxide? Lancet 1991; 337: 776-8.
2. Perez-Ruiz M, Ros J, Morales-Ruiz M et al. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology 1999; 29: 1057-63.
3. Sumanovski LT, Battegay E, Stumm M, van der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: Role of nitric oxide. Hepatology 1999; 29: 1044-9.
4. Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: Role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001; 34: 644-50.
5. Cejudo-Martin P, Ros J, Navasa M et al. Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2001; 34: 487-93.
6. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-94.
7. Fernandez M, Mejias M, Angermayr B et al. F receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005; 43: 98-103.
8. Geerts AM, De Vriese AS, Vanheule E et al. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: An in vivo study. Liver Int 2006; 26: 889-98.
9. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
10. Cardenas ME, Zhu D, Heitman J. Molecular mechanisms of immunosuppression by cyclosporin, FK506 and rapamycin. Curr Opin Nephrol Hypertens 1995; 4: 472-7.
11. Sehgal SN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995; 17: 660-5.
12. Kahan BD. Sirolimus: A ten-year perspective. Transplant Proc 2004; 36: 71-5.
13. Stephan S, Datta K, Wang E et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 2004; 10: 6993-7000.
14. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6.
15. Schumacher G, Oidtmann M, Rosewicz S et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002; 34: 1392-3.
16. Law BK. Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005; 56: 47-60.
17. Guba M, Von Beitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
18. Guba M, Koehl GE, Neppl E et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005; 18: 89-94.
19. Colle I, De Vriese AS, Van Vlierberghe H, Lameire N, De Vos M. Vascular hyporesponsiveness in the mesenteric artery of rats with cirrhosis and portal hypertension: An in vivo study. Eur J Gastroenterol Hepatol 2004; 16: 139-45.
20. Zhu J, Wu J, Frizell E et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117: 1198-204.
21. Biecker E, De Gottardi A, Neef M et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: Analysis of the underlying mechanisms. J Pharmacol Exp Ther 2005; 313: 952-61.
22. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786-96.
23. Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 2007; 46: 1208-17.
24. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17: 596-603.
25. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-68.
26. Phung TL, Ziv K, Dabydeen D et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10: 159-70.
27. Morales-Ruiz M, Tugues S, Cejudo-Martin P et al. Ascites from cirrhotic patients induces angiogenesis through the phopshoinositide 3-kinase/Akt signaling pathway. J Hepatol 2005; 43: 85-91.
28. Tazi KA, Moreau R, Hervé P et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005; 129: 303-14.
29. Kawanaka H, Jones MK, Szabo IL et al. Activation of eNOS in rat portal hypertensive gastric mucosa is mediated by TNF-alpha via the PI3-kinase-Akt signaling pathway. Hepatology 2002; 35: 393-402.
30. Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. Upregulation of TNF-alpha production signaling pathways in monocytes from patient with advanced cirrhosis: Possible role of Akt and IRAK-M. J Hepatol 2006; 45: 280-9.
31. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular growth factor and its transcriptional activator, hypoxia inducible factor-1a, through a pathway involving phosphoinositide-3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767-75.
32. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang B. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1a, HDM2, and p70SK1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 2004; 29: 45643-51.
33. Lu DY, Liou HC, Tang CH, Fu WM. Hypoxia-induced iNOS expression in microglia is regulated by the PI3-kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1a. Biochem Pharmacol 2006; 72: 992-1000.
34. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signalin. FASEB 2002; 16: 771-80.